Xencor | XNCR - Equity Capital And Reserves


Xencor reported $515.63M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -6.66B 3.39B Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Amgen USD 9.19B 532M Mar/2026
Arrowhead Research USD 613.98M 45.56M Mar/2026
AstraZeneca USD 47.33B 1.33B Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Cytokinetics USD -826.57M 166.94M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
J&J USD 81.19B 358M Mar/2026
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
MacroGenics USD 21.2M 34.39M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Xencor USD 515.63M 119.95M Mar/2026